Phibro Animal Health (NASDAQ:PAHC) Price Target Raised to $25.00

Phibro Animal Health (NASDAQ:PAHC) had its price target lifted by investment analysts at Morgan Stanley from $20.00 to $25.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 17.54% from the stock’s previous close.

A number of other brokerages have also commented on PAHC. Barclays increased their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Bank of America upped their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. began coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective for the company. Finally, StockNews.com cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $21.27 on Tuesday. The company’s fifty day moving average price is $23.63 and its 200-day moving average price is $20.66. The firm has a market capitalization of $861.50 million, a price-to-earnings ratio of 49.47, a PEG ratio of 0.58 and a beta of 0.51. Phibro Animal Health has a one year low of $10.03 and a one year high of $25.98. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in Phibro Animal Health by 3.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after buying an additional 729 shares during the period. CWM LLC boosted its position in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock valued at $37,000 after buying an additional 1,035 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after buying an additional 1,522 shares during the period. Public Sector Pension Investment Board boosted its position in Phibro Animal Health by 6.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 44,796 shares of the company’s stock valued at $751,000 after buying an additional 2,583 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its position in Phibro Animal Health by 1.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock valued at $3,931,000 after buying an additional 2,971 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.